Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date January 14, 2022 · Filed January 18, 2022
Section 16 reporting ended · disclosed 2022-01-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 264,324 |
Reported balance
Holding disclosure · report date 2022-01-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 264,324 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 26,705 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · derivative · entry 8 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,123 Underlying: Common Stock · 26,705 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,692 | $0.00 Strike: $19.47 | $0.00 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · derivative · entry 7 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,692 shares Expires 2021-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 17,692 | $32.47 | $574,459.24 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 17,692 | $19.47 | $344,463.24 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 5,603 | $32.29 | $180,920.87 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 5,603 | $26.49 | $148,423.47 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 26,705 | $32.79 | $875,656.95 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 26,705 | $26.49 | $707,415.45 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,424 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · derivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,828 Underlying: Common Stock · 30,424 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,884 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · derivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,884 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 1,884 | $31.99 | $60,269.16 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 1,884 | $26.49 | $49,907.16 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 30,424 | $32.29 | $982,390.96 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 30,424 | $26.49 | $805,931.76 |
DisclosureSEC source: 0001219036-21-000014 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,973 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000012 · edgardoc.xml · derivative · entry 9 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,252 Underlying: Common Stock · 3,973 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 948 | $0.00 Strike: $19.47 | $0.00 |
DisclosureSEC source: 0001219036-21-000012 · edgardoc.xml · derivative · entry 8 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,692 Underlying: Common Stock · 948 shares Expires 2021-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,891 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000012 · edgardoc.xml · derivative · entry 7 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,884 Underlying: Common Stock · 1,891 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 948 | $32.49 | $30,804.03 |
DisclosureSEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.48 to $32.50, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 948 | $19.47 | $18,457.56 |
DisclosureSEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 1,891 | $32.23 | $60,949.58 |
DisclosureSEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.99 to $32.50, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 1,891 | $26.49 | $50,092.59 |
DisclosureSEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 3,973 | $32.43 | $128,854.72 |
DisclosureSEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.30 to $32.72, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 21:50 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 3,973 | $26.49 | $105,244.77 |
DisclosureSEC source: 0001219036-21-000012 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 00:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 28,640 | $0.00 Strike: $19.47 | $0.00 |
DisclosureSEC source: 0001219036-21-000010 · edgardoc.xml · derivative · entry 7 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,640 Underlying: Common Stock · 28,640 shares Expires 2021-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 00:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 21,360 | $0.00 Strike: $19.47 | $0.00 |
DisclosureSEC source: 0001219036-21-000010 · edgardoc.xml · derivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,280 Underlying: Common Stock · 21,360 shares Expires 2021-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 00:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 33,372 | $31.61 | $1,055,035.76 |
DisclosureSEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.30 to $31.99, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 00:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 28,640 | $31.97 | $915,620.80 |
DisclosureSEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,922 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 00:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 28,640 | $19.47 | $557,620.80 |
DisclosureSEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 00:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 21,360 | $32.47 | $693,559.20 |
DisclosureSEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,922 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 00:00 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 21,360 | $19.47 | $415,879.20 |
DisclosureSEC source: 0001219036-21-000010 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 04, 2021 Filed May 5, 2021 23:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 19,360 | $0.00 Strike: $19.47 | $0.00 |
DisclosureSEC source: 0001219036-21-000008 · edgardoc.xml · derivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,640 Underlying: Common Stock · 19,360 shares Expires 2021-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| May 04, 2021 Filed May 5, 2021 23:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 19,360 | $31.97 | $618,948.88 |
DisclosureSEC source: 0001219036-21-000008 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,922 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.97 to $31.98, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2021 Filed May 5, 2021 23:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 19,360 | $19.47 | $376,939.20 |
DisclosureSEC source: 0001219036-21-000008 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 21:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $19.47 | $0.00 |
DisclosureSEC source: 0001219036-21-000006 · edgardoc.xml · derivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 40,000 shares Expires 2021-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 21:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 40,000 | $31.47 | $1,258,800.00 |
DisclosureSEC source: 0001219036-21-000006 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,922 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 21:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 40,000 | $19.47 | $778,800.00 |
DisclosureSEC source: 0001219036-21-000006 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 19,347 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-21-000004 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,922 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 23:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 74,445 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001219036-21-000002 · edgardoc.xml · derivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,445 shares Expires 2021-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The combined Incentive Stock Option and Non-Qualified Stock Option grants vest 25% annually beginning on the first anniversary date of the option grant, subject to statutory ISO limitations. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 23:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 5,555 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001219036-21-000002 · edgardoc.xml · derivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,555 shares Expires 2021-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The combined Incentive Stock Option and Non-Qualified Stock Option grants vest 25% annually beginning on the first anniversary date of the option grant, subject to statutory ISO limitations. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 23:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 5,555 | $29.71 | $165,056.27 |
DisclosureSEC source: 0001219036-21-000002 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,575 Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 23:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 5,555 | $18.00 | $99,990.00 |
DisclosureSEC source: 0001219036-21-000002 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 23:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 74,445 | $29.71 | $2,211,991.73 |
DisclosureSEC source: 0001219036-21-000002 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,575 Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 23:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 74,445 | $18.00 | $1,340,010.00 |
DisclosureSEC source: 0001219036-21-000002 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 12:06 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 39,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-20-000008 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,575 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,544 | $13.04 | $72,293.76 |
DisclosureSEC source: 0001219036-20-000006 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,379 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 26, 2020 Filed Sep 28, 2020 16:47 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 3,627 | $12.44 | $45,119.88 |
DisclosureSEC source: 0001219036-20-000004 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,923 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 16:47 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,214 | $12.44 | $52,422.16 |
DisclosureSEC source: 0001219036-20-000004 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,550 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 16:47 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,544 | $12.44 | $68,967.36 |
DisclosureSEC source: 0001219036-20-000004 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,764 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 16:47 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 32,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-20-000004 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,308 F1 · kind: Consists of performance stock units granted pursuant to the Companys 2017 Employee, Director and Consultant Equity Incentive Plan. Performance stock units initially granted on September 25, 2019, subject to accomplishment of pre-determined financial performance requirements. On September 24, 2020, the Compensation Committee determined the final award amount based on the accomplishment of the applicable financial performance requirements. Each performance stock unit represents a contingent right to receive one share of the Companys common stock, and vests 25% on September 26, 2020, 25% on September 26, 2021, 25% on September 26, 2022, and 25% on September 26, 2023. Read SEC document |
| August 12, 2020 Filed Aug 17, 2020 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 10,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-20-000002 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,508 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 50% on August 25, 2021, and 50% on August 25, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.